Key result
Circulating microRNAs show mechanistic promise as AF biomarkers but lack evidence for routine clinical use.
Why the study?
Existing AF risk scores perform inadequately for individual patients and the molecular substrate driving disease progression remains largely invisible at the bedside, raising the question of whether circulating miRNAs can translate into clinical utility as biomarkers.
Can circulating microRNAs serve as clinically useful biomarkers for diagnostic accuracy, prognostic value, and clinical decision-making in atrial fibrillation?
Can circulating microRNAs serve as clinically useful biomarkers for diagnostic accuracy, prognostic value, and clinical decision-making in atrial fibrillation?
Circulating microRNAs are promising biomarkers for atrial fibrillation due to their role in atrial fibrosis and electrical remodeling, but their clinical utility remains to be established.
No takes yet. Share an insight, caveat, or question.
miRNAs lack established clinical utility as AF biomarkers; leaves open need for prospective validation before adoption.
Çağlar Özmen (2026) conducted a review in Atrial Fibrillation. Circulating microRNAs was evaluated. Circulating microRNAs show mechanistic plausibility as biomarkers for atrial fibrillation, but further evidence is needed to translate these findings into routine clinical utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: